For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Medpace Holdings (MEDP - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Medpace Holdings is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MEDP is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 29.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that MEDP has returned about 72.23% since the start of the calendar year. In comparison, Medical companies have returned an average of 6.92%. As we can see, Medpace Holdings is performing better than its sector in the calendar year.
Looking more specifically, MEDP belongs to the Medical Services industry, which includes 31 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 31.14% so far this year, so MEDP is performing better in this area.
MEDP will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Medpace Holdings (MEDP - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Medpace Holdings is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MEDP is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for MEDP's full-year earnings has moved 29.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that MEDP has returned about 72.23% since the start of the calendar year. In comparison, Medical companies have returned an average of 6.92%. As we can see, Medpace Holdings is performing better than its sector in the calendar year.
Looking more specifically, MEDP belongs to the Medical Services industry, which includes 31 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 31.14% so far this year, so MEDP is performing better in this area.
MEDP will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MEDP - FREE